| British
Thyroid Association Pitt-Rivers Lecture |
| 08.30 - 09.15 |
Clyde Auditorium |
Chair: Lazarus J (Cardiff)
|
| S4 |
08.30 |
The
Na+/I- - symporter (NIS): Physiological and pathophysiological implications
Carrasco N (New York), Dohan O, De la Vieja A, Riedel C, Paroder
V, Reed M & Smit J
|
| TEA/COFFEE |
| 09.15 - 09.45 |
Hall 2
|
| Oral
Communications 5: Thyroid and calcium |
| 09.45 - 11.45 |
Carron Room |
Chair: Sheppard M (Birmingham) & Morris
J (Rochester)
|
| OC33 |
09.45 |
Contrasting
skeletal phenotypes in mice with an identical mutation targeted to either
the TRa or TRb gene
O'Shea PJ, Harvey CB, Suzuki H, Kaneshige M, Kaneshige K, Cheng
S-y & Williams GR |
| OC34 |
10.00 |
Abnormalities
of thyroid function in the POMC-null mouse
Martin NM, Small CJ, Sajedi A, Ghatei MA, Hochgeschwender U & Bloom
SR
NOVARTIS AWARD WINNER (NP2) ALSO PRESENTED IN A DEDICATED
POSTER SESSION IN HALL 2 ON TUESDAY 25 MARCH AT 12.45. |
| OC35 |
10.15 |
Five
human thyroid hormone receptor beta1 5'-UTR isoforms differentially regulate
levels of gene expression and protein translation in individual tissues
Frankton S, Gleason LJ, Harvey CB & Williams GR |
| OC36 |
10.30 |
Prophylactic
steroids are unnecessary in patients with thyroid-associated ophthalmopathy
receiving radioiodine therapy
Perros P, Neoh C, Frewin S, Kendall-Taylor P & Dickinson AJ |
| OC37 |
10.45 |
Sodium-iodide
(NIS) gene expression is a potential prognostic indicator for thyroid
cancer and is inhibited by pituitary tumor transforming gene (PTTG)
Boelaert K, Eggo MC, Gittoes NJ, Watkinson JC, Sheppard MC, Franklyn
JA & McCabe CJ |
| OC38 |
11.00 |
Idiopathic
(normocalcaemic) hypercalciuric nephrolithiasis due to an activating
calcium sensing receptor mutation
Christie PT, Curley AJ, Harding B, Bowl MR, Turner JJO, Cappuccio
FP, Langman CB, Saggar AK, Taylor T & Thakker RV |
| OC39 |
11.15 |
Parafibromin
germline mutations in patients with parathyroid tumours
Bradley KJ, Cavaco BM, Besser GM, Young A & Thakker RV
MICHAEL WHITE MEMORIAL PRIZE WINNER |
| OC40 |
11.30 |
Matrix
metalloproteinase 13 (MMP13) mutation causes spondyloepimetaphyseal dysplasia
(SEMD), Missouri variant
Kennedy AM, Christie PT, Harding B, Pannett AAJ, Dearlove A, Whyte
MP & Thakker RV
|
| Clinical
Management Workshop: Management of craniopharyngioma - medical, surgical
and radiotherapy |
| 09.45 - 11.45 |
Clyde Auditorium |
Chair: Stanhope R (London)
|
| S41 |
09.45 |
Hypothalamic
syndromes: Their investigation and treatment in comparison with craniopharyngiomas
Grossman AB (London) |
| S42 |
10.25 |
To
irradiate or not to irradiate craniopharyngiomas
Erfurth EM (Lund) |
| S43 |
11.05 |
Quality
of survival and prognosis for children with craniopharyngioma
Price DA (Manchester)
|
| Symposium
6: Prolactin: novel aspects |
| 09.45 - 11.45 |
Forth Room |
Chair: Flint D (Ayr)
|
| S24 |
09.45 |
Regulation
of prolactin gene expression
Davis JRE (Manchester) & White MRH |
| S25 |
10.15 |
Prolactin
receptor expression and prolactin-mediated effects in adipose tissue
Billig H (Göteborg), Svensson L & Ling C |
| S26 |
10.45 |
Role
and regulation of decidual PRL expression: Implications for pregnancy
failure
Brosens J (London) |
| S27 |
11.15 |
PRL
and its antagonist: The yin and yang of growth versus differentiation
Walker AM (Riverside)
|
| Annual General Meeting
of the British Thyroid Association |
| 11.45 - 13.15 |
Clyde Auditorium
|
| LUNCH |
| 11.45 - 13.15 |
Hall 2
|
| Attended Posters (odd
numbers) |
| 12.15 - 13.15 |
Hall 2 |
|
Poster Details
|
| Molecular
Endocrinology Workshop: Exploiting bacteriophage |
| 13.15 - 14.15 |
Forth Room |
Chair: Baker A (Glasgow)
|
|
Peptide targeted vectors
for gene therapy
Hart S (London) |
| |
| Novartis
Satellite Symposium |
| 13.15 - 14.15 |
Clyde Auditorium (further
details)
|
| Symposium
7: Hot topics |
| 14.15 - 15.45 |
Forth Room |
Chair: Walker B (Edinburgh)
|
| S28 |
14.15 |
Effects
of interleukin-6 (IL-6) deficiency on exercise capacity in mice
Jansson J (Gothenburg), Faldt J, Wernstedt I, Bergstrom G & Fitzgerald
S |
| S29 |
14.45 |
Risk
of cancer in patients treated with human pituitary growth hormone in
the UK, 1959-85: A cohort study
Preece MA (London), Swerdlow AJ, Higgins CD & Adlard P |
| S30 |
15.15 |
A
natural product that lowers cholesterol as an antagonist for the bile
acid receptor FXR
Urizar NL, Liverman A, Ordentlich P, Yan Y, Heyman RA, Gonzalez
FJ, Mangelsdorf DJ & Moore DD (Houston)
|
| Symposium
8: Radioiodine biology in the 21st century |
| 14.15 - 15.45 |
Clyde Auditorium |
Chair: Carrasco N (New York)
|
| S31 |
14.15 |
Thyroid
eye disease and radioiodine therapy for Graves' hyperthyroidism
Bartalena L (Pisa) |
| S32 |
14.45 |
NIS
and thyroid cancer
Morris JC (Rochester) |
| S33 |
15.15 |
The
molecular genetics of post Chernobyl thyroid cancer
Thomas GA (Swansea)
|
| Young
Endocrinologists Workshop: Alternative careers for endocrine researchers |
| 14.15 - 15.45 |
Carron Room |
Chair: Doufexis M (London) & Storr H
(London)
|
| S49 |
14.15 |
Clinical
biochemistry
Parsons M (London) |
| S50 |
14.35 |
Research
for clinical paediatric endocrinologists
Blair JC (London) & Savage MO |
| S51 |
14.55 |
Sales
opportunities in biotech firms
Jackson S (London) |
| S52 |
15.15 |
A
career in medical education and communication
Farrow SM (London)
|
| Clinical
Endocrinology Trust Lecture |
| 16.00 - 16.45 |
Clyde Auditorium |
Chair: Wass J (Oxford) |
| S5 |
16.00 |
Growth
hormone outgrows growth
Shalet SM (Manchester)
|
| Meet
the Endocrinologist Session for Local GPs |
| Supported by an unrestricted
EDUCATIONAL Grant From Eli Lilly ICOS |
| 18.15 - 21.30 |
Forth Room |
|
Erectile dysfunction |
|
PCOS |
|
Bone disease |
| |
| Informal Curry Evening
(entrance by ticket only) |
| 20.00 |
Café India |